#316 - What Should You Actually Do About High Cholesterol? | Dr. Seth Martin & Mike Haney
LEVELS – A Whole New LevelShow Notes
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Free course: Improve your metabolic health Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
What We Cover: Why the evidence that LDL and ApoB-containing particles cause atherosclerosis is so strong What “lower for longer” means and how the new LDL and ApoB goals change with cardiovascular risk When ApoB adds useful information beyond a standard lipid panel Why the guidelines recommend against routine LDL particle-size testing How PREVENT risk scores and coronary calcium scans can help decide when treatment makes sense What decades of statin research tell us about benefits, muscle symptoms, and diabetes risk How much lifestyle changes typically move cholesterol, and when non-statin drugs enter the picture Why common heart-health supplements don’t have the evidence behind proven lipid-lowering therapies
🎙️ About the Guest: Dr. Seth Martin is a professor of medicine and preventive cardiologist at Johns Hopkins, where he directs the Advanced Lipid Disorders Program and Digital Health and AI Lab at the Ciccarone Center for the Prevention of Cardiovascular Disease. He is a co-developer of the widely used Martin-Hopkins LDL cholesterol equation and served on the writing committee for the 2026 ACC/AHA dyslipidemia guideline.
📍What Dr. Seth Martin & Mike Haney discussed: 00:04 - LDL and ApoB are causal. Lower for longer 07:10 - Guidelines set the standard. Not your doctor 11:40 - 2026 shift: earlier treatment, PREVENT, lower goals 17:01 - LDL near zero does not eliminate cholesterol 19:59 - Hard numbers are back, and lower 23:05 - ApoB if a high result changes treatment 27:42 - No trial says treat particle size instead of LDL 34:51 - PREVENT is for people not already high risk 38:52 - Calcium 300 can push the goals. Zero can mean lifestyle first 44:29 - The 3% statin line, and the choice just under it 51:22 - Muscle symptoms uncommon. Statin can move prediabetes diagnosis earlier 56:21 - Lifestyle often lowers LDL about 10%, not the whole benefit 59:05 - Other proven drugs when a statin is not enough 1:05:31 - Statin beat the supplements. Fish oil can raise AFib risk
🔗 Helpful Links: 2026 Guideline on the Management of Dyslipidemia: Read the guideline and supporting materials The New Cholesterol Guideline: What to Know — Johns Hopkins: Read the Johns Hopkins summary PREVENT-ASCVD Calculator.: Use the PREVENT calculator Martin-Hopkins LDL Equation: Learn about the Martin-Hopkins method SPORT Trial — JACC (2022): Read the SPORT trial
Watch the conversation: https://youtu.be/vRfhof5dOZw Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.
From a single blood sample, new proteomic tools can now measure thousands of proteins at once. Dr. Tony Wyss-Coray’s lab is using that flood of data, together with machine learning, to build a much higher-resolution picture of what’s happening throughout the body and where someone’s health may be headed.